illumina

Illumina Genomic Discoveries Program Brings Sophisticated Lab Experiences to High School Classrooms

Jessica Bosch fosters students’ love of science through the Illumina Genomic Discoveries program
Article

From a young age, Jessica Bosch knew she wanted to be a biology teacher. She always loved science, competing in science fairs in middle and high school. After high school, she went on to study cell molecular biology at San Diego State University and spent eight years in drug discovery research at biotech companies. But as much as she loved the science and lab-based work, she knew it was time to transition her passion and expertise into teaching.

Berry Oncology Utilizes Illumina Technology to Accelerate Early Liver Cancer Detection in China

Cancer screening gains momentum with $99 million in funding and the country’s largest liver cancer cohort study
Article

Jun Zhou is determined to make an impact on early cancer detection in China. The CEO of Berry Oncology, a subsidiary of Berry Genomics, is overseeing China’s first and only large-scale, forward-looking cohort study of early liver cancer screening based on next-generation sequencing (NGS) technology. It is also one of the largest and fastest-growing prospective cohort studies of liver cancer in the world.

Illumina’s Shanghai Family Day Educates Kids on DNA and STEM Activities

Multimedia with summary

On August 13, Illumina Shanghai Family Open Day was held in Illumina’s Shanghai office. Over 160 colleagues and families joined the fun summer party!

The office, where Illumina employees meet for daily meetings, trainings, and experiments, was decorated for adults and kids to unleash imagination and creativity.

In addition to a series of fun STEM activities and games, the kids put on lab coats and goggles to experience life as a scientist. Employee volunteers conducted a banana DNA extraction experiment and the kids visited the lab to experience the wonders of DNA!

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review
Press Release

SAN DIEGO, August 19, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.

Illumina's Interns Contribute Over 800 Hours on Social Impact Projects

Blog

Illumina interns put our culture of giving back into action with their social impact projects this summer. Embedding CSR into how we do business even translates to our intern program!

Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All

Article

In the future, what if you could sequence your cancer patients by the thousands, provide answers quicker, and deliver more effective treatment and better care—on a routine basis? For Providence, the nation’s third largest not-for-profit health system, that future is the present.

Illumina Donates Next-Generation Sequencing Capabilities to Support Indigenous Scientists

Next-generation sequencing is helping Native nations with sovereignty and genetic research
Article

International Day of World’s Indigenous Peoples is celebrated each year on August 9. On this day, people from around the world are encouraged to spread the United Nation’s message on the protection and promotion of the rights of indigenous peoples. This year, Illumina is honored to highlight one of their nonprofit partners, and recent donation recipient, Native BioData Consortium (NBDC).

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India

Press Release

SAN DIEGO, August 4, 2021 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to help expand SARS-CoV-2 sequencing capabilities in the region and support the broader genomic surveillance effort across India. Kasturba Hospital was the first hospital in Mumbai to begin sequencing SARS-CoV-2 this year and will examine how variants of the virus are being spread across India.

Illumina Coordinates Research and Efforts in China’s Rare Disease Community

Article

There are nearly 7,000 types of rare diseases, and about 80 percent of them are caused by genetic mutations. “Compared with common diseases, rare diseases are difficult to diagnose from the very beginning,” says Yiou Wang, Founder of the Illness Challenge Foundation.

Illumina Celebrates National Intern Day

Blog

"Happy #NationalInternDay to the 73 interns at Illumina and to all interns everywhere - the leaders and innovators of tomorrow!

Pages

Subscribe to illumina